LRRK2 expression in idiopathic and G2019S positive Parkinson's disease subjects: A morphological and quantitative study

Neuropathology and Applied Neurobiology

Volumn 37, Issue 7, 2011, Pages 777-790

  Sharma, S ^a,c   Bandopadhyay, R ^b   Lashley, T ^a   Renton, A E M ^a,c   Kingsbury, A E ^b   Kumaran, R ^b   Kallis, C ^a,d   Vilarino Guell C ^a,e   O'Sullivan, S S ^b   Lees, A J ^b   Revesz, T ^a   Wood, N W ^a   Holton, J L ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

^d QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^e UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

G2019S mutation; Lewy bodies; LRRK2; LRRK2 mRNA; LRRK2 protein; Parkinson's disease

Indexed keywords

LEUCINE RICH REPEAT KINASE 2; MESSENGER RNA;

AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CORPUS STRIATUM; FEMALE; GENE MUTATION; HUMAN; HUMAN TISSUE; IDIOPATHIC DISEASE; IMMUNOHISTOCHEMISTRY; LEWY BODY; LIMBIC CORTEX; MALE; NEOCORTEX; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; QUANTITATIVE STUDY; REAL TIME POLYMERASE CHAIN REACTION; SUBSTANTIA NIGRA;

BRAIN; FEMALE; HUMANS; MALE; MUTATION; NEURONS; PARKINSON DISEASE; PROTEIN-SERINE-THREONINE KINASES;

EID: 79960661378     PISSN: 03051846     EISSN: 13652990     Source Type: Journal    
DOI: 10.1111/j.1365-2990.2011.01187.x     Document Type: Article

References (71)

1. Lesage S, Brice A. Parkinson's disease: from monogenic forms to genetic susceptibility factors. Hum Mol Genet 2009; 18: R48-59.
2. Singleton AB, Farrer M, Johnson J, Singleton A, Hague S, Kachergus J, Hulihan M, Peuralinna T, Dutra A, Nussbaum R, Lincoln S, Crawley A, Hanson M, Maraganore D, Adler C, Cookson MR, Muenter M, Baptista M, Miller D, Blancato J, Hardy J, Gwinn-Hardy K. alpha-Synuclein locus triplication causes Parkinson's disease. Science 2003; 302: 841.
3. Kumaran R, Vandrovcova J, Luk C, Sharma S, Renton A, Wood NW, Hardy JA, Lees AJ, Bandopadhyay R. Differential DJ-1 gene expression in Parkinson's disease. Neurobiol Dis 2009; 36: 393-400.
4. Moran LB, Duke DC, Deprez M, Dexter DT, Pearce RKB, Graeber MB. Whole genome expression profiling of the medial and lateral substantia nigra in Parkinson's disease. Neurogenetics 2006; 7: 1-11.
5. Simunovic F, Yi M, Wang Y, Macey L, Brown LT, Krichevsky AM, Andersen SL, Stephens RM, Benes FM, Sonntag KC. Gene expression profiling of substantia nigra dopamine neurons: further insights into Parkinson's disease pathology. Brain 2009; 132: 1795-809.
6. Bossers K, Meerhoff G, Balesar R, van Dongen JW, Kruse CG, Swaab DF, Verhaagen J. Analysis of gene expression in Parkinson's disease: possible involvement of neurotrophic support and axon guidance in dopaminergic cell death. Brain Pathol 2009; 19: 91-107.
7. Paisan-Ruiz C, Jain S, Evans E, Gilks W, Simon J, van der Brug M, Lopez de Munain A, Aparicio S, Gil A, Khan N. Cloning of the gene containing mutations that cause PARK8-linked Parkinson's disease. Neuron 2004; 44: 595-600.
8. Zimprich A, Biskup S, Leitner P, Lichtner P, Farrer M, Lincoln S, Kachergus J, Hulihan M, Uitti R, Calne D. Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology. Neuron 2004; 44: 601-7.
9. Healy DG, Falchi M, O'Sullivan SS, Bonifati V, Durr A, Bressman S, Brice A, Aasly J, Zabetian CP, Goldwurm S, Ferreira JJ, Tolosa E, Kay DM, Klein C, Williams DR, Marras C, Lang AE, Wszolek ZK, Berciano J, Schapira AHV, Lynch T, Bhatia KP, Gasser T, Lees AJ, Wood NW. Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson's disease: a case-control study. Lancet Neurol 2008; 7: 583-90.
10. Nichols WC, Pankratz N, Hernandez D, Paisán-Ruíz C, Jain S, Halter CA, Michaels VE, Reed T, Rudolph A, Shults CW, Singleton A, Foroud T. Genetic screening for a single common LRRK2 mutation in familial Parkinson's disease. Lancet 2005; 365: 410-12.
11. Di Fonzo A, Rohé CF, Ferreira J, Chien HF, Vacca L, Stocchi F, Guedes L, Fabrizio E, Manfredi M, Vanacore N, Goldwurm S, Breedveld G, Sampaio C, Meco G, Barbosa E, Oostra BA, Bonifati V. A frequent LRRK2 gene mutation associated with autosomal dominant Parkinson's disease. Lancet 2005; 365: 412-15.
12. Gilks W, Abou-Sleiman P, Gandhi S, Jain S, Singleton A, Lees A, Shaw K, Bhatia K, Bonifati V, Quinn N. A common LRRK2 mutation in idiopathic Parkinson's disease. Lancet 2005; 365: 415-16.
13. Lesage S, Ibanez P, Lohmann E, Pollak P, Tison F, Tazir M, Leutenegger A, Guimaraes J, Bonnet A, Agid Y. G2019S LRRK2 mutation in French and North African families with Parkinson's disease. Ann Neurol 2005; 58: 784-7.
14. Ozelius L, Senthil G, Saunders-Pullman R, Ohmann E, Deligtisch A, Tagliati M, Hunt A, Klein C, Henick B, Hailpern S. LRRK2 G2019S as a cause of Parkinson's disease in Ashkenazi Jews. N Engl J Med 2006; 354: 424-5.
15. Ross O, Toft M, Whittle A, Johnson J, Papapetropoulos S, Mash D, Litvan I, Gordon M, Wszolek Z, Farrer M. Lrrk2 and Lewy body disease. Ann Neurol 2006; 59: 388-93.
16. Anand VS, Braithwaite SP. LRRK2 in Parkinson's disease: biochemical functions. FEBS J 2009; 276: 6428-35.
17. Imai Y, Gehrke S, Wang H, Takahashi R, Hasegawa K, Oota E, Lu B. Phosphorylation of 4E-BP by LRRK2 affects the maintenance of dopaminergic neurons in Drosophila. EMBO J 2008; 27: 2432-43.
18. Wang L, Xie C, Greggio E, Parisiadou L, Shim H, Sun L, Chandran J, Lin X, Lai C, Yang W, Moore DJ, Dawson TM, Dawson VL, Chiosis G, Cookson MR, Cai H. The chaperone activity of heat shock protein 90 is critical for maintaining the stability of leucine-rich repeat kinase 2. J Neurosci 2008; 28: 3384-91.
19. Jaleel M, Nichols RJ, Deak M, Campbell DG, Gillardon F, Knebel A, Alessi DR. LRRK2 phosphorylates moesin at threonine-558: characterization of how Parkinson's disease mutants affect kinase activity. Biochem J 2007; 405: 307-17.
20. MacLeod D, Dowman J, Hammond R, Leete T, Inoue K, Abeliovich A. The familial Parkinsonism gene LRRK2 regulates neurite process morphology. Neuron 2006; 52: 587-93.
21. Biskup S, Moore D, Celsi F, Higashi S, West A, Andrabi S, Kurkinen K, Yu S, Savitt J, Waldvogel H. Localization of LRRK2 to membranous and vesicular structures in mammalian brain. Ann Neurol 2006; 60: 557-69.
22. Hatano T, Kubo S, Imai S, Maeda M, Ishikawa K, Mizuno Y, Hattori N. Leucine-rich repeat kinase 2 associates with lipid rafts. Hum Mol Genet 2007; 16: 678-90.
23. Gloeckner C, Kinkl N, Schumacher A, Braun R, O'Neill E, Meitinger T, Kolch W, Prokisch H, Ueffing M. The Parkinson disease causing LRRK2 mutation I2020T is associated with increased kinase activity. Hum Mol Genet 2006; 15: 223-32.
24. West A, Moore D, Biskup S, Bugayenko A, Smith W, Ross C, Dawson V, Dawson T. Parkinson's disease-associated mutations in leucine-rich repeat kinase 2 augment kinase activity. Proc Natl Acad Sci U S A 2005; 102: 16842-7.
25. Greggio E, Cookson MR. Leucine-rich repeat kinase 2 mutations and Parkinson's disease: three questions. ASN Neuro 2009; 1. pii: e00002. doi: 10.1042/AN20090007.
26. Smith WW, Pei Z, Jiang H, Moore DJ, Liang Y, West AB, Dawson VL, Dawson TM, Ross CA. Leucine-rich repeat kinase 2 (LRRK2) interacts with parkin, and mutant LRRK2 induces neuronal degeneration. Proc Natl Acad Sci U S A 2005; 102: 18676-81.
27. Greggio E, Jain S, Kingsbury A, Bandopadhyay R, Lewis P, Kaganovich A, van der Brug M, Beilina A, Blackinton J, Thomas K. Kinase activity is required for the toxic effects of mutant LRRK2/dardarin. Neurobiol Dis 2006; 23: 329-41.
28. Smith WW, Pei Z, Jiang H, Dawson VL, Dawson TM, Ross CA. Kinase activity of mutant LRRK2 mediates neuronal toxicity. Nat Neurosci 2006; 9: 1231-3.
29. Galter D, Westerlund M, Carmine A, Lindqvist E, Sydow O, Olson L. LRRK2 expression linked to dopamine-innervated areas. Ann Neurol 2006; 59: 714-19.
30. Melrose H, Lincoln S, Tyndall G, Dickson D, Farrer M. Anatomical localization of leucine-rich repeat kinase 2 in mouse brain. Neuroscience 2006; 139: 791-4.
31. Simon-Sanchez J, Herranz-Perez V, Olucha-Bordonau F, Perez-Tur J. LRRK2 is expressed in areas affected by Parkinson's disease in the adult mouse brain. Eur J Neurosci 2006; 23: 659-66.
32. Miklossy J, Arai T, Guo J, Klegeris A, Yu S, McGeer E, McGeer P. LRRK2 expression in normal and pathologic human brain and in human cell lines. J Neuropathol Exp Neurol 2006; 65: 953-63.
33. Zhu X, Babar A, Siedlak SL, Yang Q, Ito G, Iwatsubo T, Smith MA, Perry G, Chen SG. LRRK2 in Parkinson's disease and dementia with Lewy bodies. Mol Neurodegener 2006; 1: 17. doi: 10.1186/1750-1326-1-17.
34. Higashi S, Moore D, Colebrooke R, Biskup S, Dawson V, Arai H, Dawson T, Emson P. Expression and localization of Parkinson's disease-associated leucine-rich repeat kinase 2 in the mouse brain. J Neurochem 2007; 100: 368-81.
35. Higashi S, Biskup S, West A, Trinkaus D, Dawson V, Faull R, Waldvogel H, Arai H, Dawson T, Moore D. Localization of Parkinson's disease-associated LRRK2 in normal and pathological human brain. Brain Res 2007; 1155: 208-19.
36. Melrose H, Kent C, Taylor J, Dachsel J, Hinkle K, Lincoln S, Mok S, Culvenor J, Masters C, Tyndall G. A comparative analysis of leucine-rich repeat kinase 2 (Lrrk2) expression in mouse brain and Lewy body disease. Neuroscience 2007; 147: 1047-58.
37. Alegre-Abarrategui J, Ansorge O, Esiri M, Wade-Martins R. LRRK2 is a component of granular alpha-synuclein pathology in the brainstem of Parkinson's disease. Neuropathol Appl Neurobiol 2008; 34: 272-83.
38. Santpere G, Ferrer I. LRRK2 and neurodegeneration. Acta Neuropathol 2009; 117: 227-46.
39. Vitte J, Traver S, De Paula AM, Lesage S, Rovelli G, Corti O, Duyckaerts C, Brice A. Leucine-rich repeat kinase 2 is associated with the endoplasmic reticulum in dopaminergic neurons and accumulates in the core of Lewy bodies in Parkinson disease. J Neuropathol Exp Neurol 2010; 69: 959-72.
40. Giasson B, Covy J, Bonini N, Hurtig H, Farrer M, Trojanowski J, Van Deerlin V. Biochemical and pathological characterization of Lrrk2. Ann Neurol 2006; 59: 315-22.
41. Huang Y, Song YJC, Murphy K, Holton JL, Lashley T, Revesz T, Gai W, Halliday GM. LRRK2 and parkin immunoreactivity in multiple system atrophy inclusions. Acta Neuropathol 2008; 116: 639-46.
42. Silveira-Moriyama L, Guedes LC, Kingsbury A, Ayling H, Shaw K, Barbosa ER, Bonifati V, Quinn NP, Abou-Sleiman P, Wood NW, Petrie A, Sampaio C, Ferreira JJ, Holton J, Revesz T, Lees AJ. Hyposmia in G2019S LRRK2-related parkinsonism: clinical and pathologic data. Neurology 2008; 71: 1021-6.
43. Lashley T, Revesz T, Plant G, Bandopadhyay R, Lees AJ, Frangione B, Wood NW, de Silva R, Ghiso J, Rostagno A, Holton JL. Expression of BRI2 mRNA and protein in normal human brain and familial British dementia: its relevance to the pathogenesis of disease. Neuropathol Appl Neurobiol 2008; 34: 492-505.
44. McKeith IG. Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the Consortium on DLB International Workshop. J Alzheimers Dis 2006; 9: 417-23.
45. Jesnowski R, Backhaus C, Ringel J, Löhr M. Ribosomal highly basic 23-kDa protein as a reliable standard for gene expression analysis. Pancreatology 2002; 2: 421-4.
46. Meldgaard M, Fenger C, Lambertsen KL, Pedersen MD, Ladeby R, Finsen B. Validation of two reference genes for mRNA level studies of murine disease models in neurobiology. J Neurosci Methods 2006; 156: 101-10.
47. Ohl F, Jung M, Xu C, Stephan C, Rabien A, Burkhardt M, Nitsche A, Kristiansen G, Loening SA, Radonić A, Jung K. Gene expression studies in prostate cancer tissue: which reference gene should be selected for normalization? J Mol Med 2005; 83: 1014-24.
48. Andersen CL, Jensen JL, Ørntoft TF. Normalization of real-time quantitative reverse transcription-PCR data: a model-based variance estimation approach to identify genes suited for normalization, applied to bladder and colon cancer data sets. Cancer Res 2004; 64: 5245-50.
49. Simes R. An improved Bonferroni procedure for multiple tests of significance. Biometrika 1986; 73: 751-4.
50. Kingsbury AE, Foster OJ, Nisbet AP, Cairns N, Bray L, Eve DJ, Lees AJ, Marsden CD. Tissue pH as an indicator of mRNA preservation in human post-mortem brain. Brain Res Mol Brain Res 1995; 28: 311-18.
51. Dachsel JC, Nishioka K, Vilariño-Güell C, Lincoln SJ, Soto-Ortolaza AI, Kachergus J, Hinkle KM, Heckman MG, Jasinska-Myga B, Taylor JP, Dickson DW, Gibson RA, Hentati F, Ross OA, Farrer MJ. Heterodimerization of Lrrk1-Lrrk2: implications for LRRK2-associated Parkinson disease. Mech Ageing Dev 2010; 131: 210-14.
52. Gandhi S, Muqit MMK, Stanyer L, Healy DG, Abou-Sleiman PM, Hargreaves I, Heales S, Ganguly M, Parsons L, Lees AJ, Latchman DS, Holton JL, Wood NW, Revesz T. PINK1 protein in normal human brain and Parkinson's disease. Brain 2006; 129: 1720-31.
53. Qing H, Zhang Y, Deng Y, McGeer EG, McGeer PL. Lrrk2 interaction with alpha-synuclein in diffuse Lewy body disease. Biochem Biophys Res Commun 2009; 390: 1229-34.
54. Lin X, Parisiadou L, Gu X, Wang L, Shim H, Sun L, Xie C, Long C, Yang W, Ding J, Chen ZZ, Gallant PE, Tao-Cheng J, Rudow G, Troncoso JC, Liu Z, Li Z, Cai H. Leucine-rich repeat kinase 2 regulates the progression of neuropathology induced by Parkinson's-disease-related mutant alpha-synuclein. Neuron 2009; 64: 807-27.
55. Gloeckner CJ, Schumacher A, Boldt K, Ueffing M. The Parkinson disease-associated protein kinase LRRK2 exhibits MAPKKK activity and phosphorylates MKK3/6 and MKK4/7, in vitro. J Neurochem 2009; 109: 959-68.
56. Carballo-Carbajal I, Weber-Endress S, Rovelli G, Chan D, Wolozin B, Klein CL, Patenge N, Gasser T, Kahle PJ. Leucine-rich repeat kinase 2 induces alpha-synuclein expression via the extracellular signal-regulated kinase pathway. Cell Signal 2010; 22: 821-7.
57. Sharma S, Vilarino-Guell C, Holton J, Revesz T, Wood N. Genetic variation and the regulation of gene expression in Parkinson's disease. Abstr Soc Neurosci 2007. Poster No.: 891.10/Q13.
58. Hurley MJ, Patel PH, Jackson MJ, Smith LA, Rose S, Jenner P. Striatal leucine-rich repeat kinase 2 mRNA is increased in 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine-lesioned common marmosets (Callithrix jacchus) with L-3, 4-dihydroxyphenylalanine methyl ester-induced dyskinesia. Eur J Neurosci 2007; 26: 171-7.
59. Li X, Patel JC, Wang J, Avshalumov MV, Nicholson C, Buxbaum JD, Elder GA, Rice ME, Yue Z. Enhanced striatal dopamine transmission and motor performance with LRRK2 overexpression in mice is eliminated by familial Parkinson's disease mutation G2019S. J Neurosci 2010; 30: 1788-97.
60. Braak H, Del Tredici K, Rüb U, de Vos RAI, Jansen Steur ENH, Braak E. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging 2003; 24: 197-211.
61. Braak H, Bohl JR, Müller CM, Rüb U, de Vos RAI, Del Tredici K. Stanley Fahn Lecture 2005: the staging procedure for the inclusion body pathology associated with sporadic Parkinson's disease reconsidered. Mov Disord 2006; 21: 2042-51.
62. Parkkinen L, Pirttilä T, Alafuzoff I. Applicability of current staging/categorization of alpha-synuclein pathology and their clinical relevance. Acta Neuropathol 2008; 115: 399-407.
63. Dickson DW, Fujishiro H, Orr C, DelleDonne A, Josephs KA, Frigerio R, Burnett M, Parisi JE, Klos KJ, Ahlskog JE. Neuropathology of non-motor features of Parkinson disease. Parkinsonism Relat Disord 2009; 15: S1-5.
64. White LR, Toft M, Kvam SN, Farrer MJ, Aasly JO. MAPK-pathway activity, Lrrk2 G2019S, and Parkinson's disease. J Neurosci Res 2007; 85: 1288-94.
65. Andres-Mateos E, Mejias R, Sasaki M, Li X, Lin BM, Biskup S, Zhang L, Banerjee R, Thomas B, Yang L, Liu G, Beal MF, Huso DL, Dawson TM, Dawson VL. Unexpected lack of hypersensitivity in LRRK2 knock-out mice to MPTP. J Neurosci 2009; 29: 15846-50.
66. Tong Y, Yamaguchi H, Giaime E, Boyle S, Kopan R, Kelleher RJ, Shen J. Loss of leucine-rich repeat kinase 2 causes impairment of protein degradation pathways, accumulation of {alpha}-synuclein, and apoptotic cell death in aged mice. Proc Natl Acad Sci U S A 2010; 107: 9879-84.
67. Lee SB, Kim W, Lee S, Chung J. Loss of LRRK2/PARK8 induces degeneration of dopaminergic neurons in Drosophila. Biochem Biophys Res Commun 2007; 358: 534-9.
68. Liou AKF, Leak RK, Li L, Zigmond MJ. Wild-type LRRK2 but not its mutant attenuates stress-induced cell death via ERK pathway. Neurobiol Dis 2008; 32: 116-24.
69. Saha S, Guillily MD, Ferree A, Lanceta J, Chan D, Ghosh J, Hsu CH, Segal L, Raghavan K, Matsumoto K, Hisamoto N, Kuwahara T, Iwatsubo T, Moore L, Goldstein L, Cookson M, Wolozin B. LRRK2 modulates vulnerability to mitochondrial dysfunction in Caenorhabditis elegans. J Neurosci 2009; 29: 9210-18.
70. Hardy J. Genetic analysis of pathways to Parkinson disease. Neuron 2010; 68: 201-6.
71. Guo H, Ingolia NT, Weissman JS, Bartel DP. Mammalian microRNAs predominantly act to decrease target mRNA levels. Nature 2010; 466: 835-40.